VTRLY Quote, Financials, Valuation and Earnings

BioArctic AB has a net margin of 12.22% compared to Vitrolife AB's net margin of -65.15%. Vitrolife AB's return on equity of 3.26% beat BioArctic AB's return on equity of 59.48%.

Vitrolife AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Vitrolife AB has higher upside potential than BioArctic AB, analysts believe Vitrolife AB is more attractive than BioArctic AB.

Vitrolife AB has a beta of 1.353, which suggesting that the stock is 35.276% more volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vitrolife AB has a quarterly dividend of $0.11 per share corresponding to a yield of 0.76%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vitrolife AB pays 15.92% of its earnings as a dividend. BioArctic AB pays out -- of its earnings as a dividend. Vitrolife AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vitrolife AB quarterly revenues are $87.7M, which are larger than BioArctic AB quarterly revenues of $14M. Vitrolife AB's net income of $10.7M is higher than BioArctic AB's net income of -$9.1M. Notably, Vitrolife AB's price-to-earnings ratio is 47.12x while BioArctic AB's PE ratio is 32.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vitrolife AB is 5.90x versus 16.63x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Camurus AB has a net margin of 12.22% compared to Vitrolife AB's net margin of 33.97%. Vitrolife AB's return on equity of 3.26% beat Camurus AB's return on equity of 21.63%.

Vitrolife AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Vitrolife AB has higher upside potential than Camurus AB, analysts believe Vitrolife AB is more attractive than Camurus AB.

Vitrolife AB has a beta of 1.353, which suggesting that the stock is 35.276% more volatile than S&P 500. In comparison Camurus AB has a beta of 0.933, suggesting its less volatile than the S&P 500 by 6.658%.

Vitrolife AB has a quarterly dividend of $0.11 per share corresponding to a yield of 0.76%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vitrolife AB pays 15.92% of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend. Vitrolife AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vitrolife AB quarterly revenues are $87.7M, which are larger than Camurus AB quarterly revenues of $59.6M. Vitrolife AB's net income of $10.7M is lower than Camurus AB's net income of $20.2M. Notably, Vitrolife AB's price-to-earnings ratio is 47.12x while Camurus AB's PE ratio is 53.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vitrolife AB is 5.90x versus 17.95x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.

Hansa Biopharma AB has a net margin of 12.22% compared to Vitrolife AB's net margin of -481.29%. Vitrolife AB's return on equity of 3.26% beat Hansa Biopharma AB's return on equity of --.

Vitrolife AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Vitrolife AB has higher upside potential than Hansa Biopharma AB, analysts believe Vitrolife AB is more attractive than Hansa Biopharma AB.

Vitrolife AB has a beta of 1.353, which suggesting that the stock is 35.276% more volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.402, suggesting its less volatile than the S&P 500 by 59.764%.

Vitrolife AB has a quarterly dividend of $0.11 per share corresponding to a yield of 0.76%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vitrolife AB pays 15.92% of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend. Vitrolife AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vitrolife AB quarterly revenues are $87.7M, which are larger than Hansa Biopharma AB quarterly revenues of $3.2M. Vitrolife AB's net income of $10.7M is higher than Hansa Biopharma AB's net income of -$15.6M. Notably, Vitrolife AB's price-to-earnings ratio is 47.12x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vitrolife AB is 5.90x versus 12.08x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.

Orexo AB has a net margin of 12.22% compared to Vitrolife AB's net margin of -33.67%. Vitrolife AB's return on equity of 3.26% beat Orexo AB's return on equity of -134.37%.

Vitrolife AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Orexo AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Vitrolife AB has higher upside potential than Orexo AB, analysts believe Vitrolife AB is more attractive than Orexo AB.

Vitrolife AB has a beta of 1.353, which suggesting that the stock is 35.276% more volatile than S&P 500. In comparison Orexo AB has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.934%.

Vitrolife AB has a quarterly dividend of $0.11 per share corresponding to a yield of 0.76%. Orexo AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vitrolife AB pays 15.92% of its earnings as a dividend. Orexo AB pays out -- of its earnings as a dividend. Vitrolife AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vitrolife AB quarterly revenues are $87.7M, which are larger than Orexo AB quarterly revenues of $12.2M. Vitrolife AB's net income of $10.7M is higher than Orexo AB's net income of -$4.1M. Notably, Vitrolife AB's price-to-earnings ratio is 47.12x while Orexo AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vitrolife AB is 5.90x versus 1.31x for Orexo AB. Usually stocks with elevated PS ratios are considered overvalued.